New combo aims to slow bone metastases in prostate cancer

NCT ID NCT03317392

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The trial first finds the safest dose, then checks if the combo delays cancer progression. About 132 men are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib and radium-223
What this could lead to: If it works, this combination could slow cancer growth and extend time without progression for men with advanced prostate cancer that has spread to bone.
What could go wrong: This is an early-phase trial (phase 1/2) with a small number of participants, so the benefits are uncertain. Combining two drugs may also increase side effects like bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Show contact details

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064, United States
University of Kansas Cancer Center - North

Kansas City, Missouri, 64154, United States
University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, Missouri, 64116, United States
University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210, United States
University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Maryland/Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.